Phase I study of Yttrium-90 labeled HuM19 [lintuzumab-Y-90] combined with etoposide as a conditioning regimen for autologous stem cell transplantation in patients with advanced myelodysplastic syndrome and refractory leukemia
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2010
At a glance
- Drugs Lintuzumab Y-90 (Primary) ; Etoposide; Filgrastim
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 27 Dec 2007 New trial record.